Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics and Econometrics,General Medicine
Reference51 articles.
1. McConnell K, Baker T. Perceptions in oncology drug strengths and weaknesses. Oncol Bus Rev. 2008:14–7.
2. Novartis Oncology. Assessing clinical value of oncology treatments. Novartis Oncology; 2013. http://www.novartisoncology.com/ .
3. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
4. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179–90.
5. Williamson S. Patient access schemes for high-cost cancer medicines. Lancet Oncol. 2010;11(2):111–2.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献